The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
Newark, Delaware 19716, United States
1 to 5 years postmenopausal women with low bone mass
Taking blood thinners, endocrine, or neuroactive drugs
Diagnosed: Metabolic bone disease, renal disease, kidney stones, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease
Severe menopausal symptoms, serious mood alterations, sleep disturbances
Abnormal uterine bleeding, endometriosis, pelvic inflammatory disease
Endometrial polyps, and significant uterine fibroids
Smokers (≥ 20 cigarettes per day)
BMI <20 and > 30 kg/m2
Intolerance or allergic reaction to resveratrol, microcrystalline cellulose, grapes, red wine, or blueberries
Study Contact Info
Contact Listings Owner Form
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women 0 reviewsWrite Your Review
There are no reviews yet.
Write Your Review
Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention. Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks.